10x Genomics Analyst Price Targets - Benzinga

10x Genomics Inc

TXGNASDAQ

Trade with Public

Trade with Public

$81.55

-2.07-2.48%

Últ. Act.: Oct 29, 7:57 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

© 2026 Benzinga | All Rights Reserved

10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

7Buy

10Hold

1Sell

Consensus RatingNeutral# Analysts18Avg. Consensus PT$56Upside to Avg. PT-29.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Dan Brennan	PT Raise	Hold	$47→$70
Oct 13, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$40→$70
Oct 12, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$60→$100
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$52→$110
Sep 29, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$40→$90
Sep 28, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$47→$80
Sep 28, 2026	Argus Research	John Eade	Initiate	Buy	$110
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Neutral	$20→$68
Sep 1, 2026	RBC Capital	Dan Leonard	Initiate	Sector Perform	$70
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40

Analyst Ratings News

PRO
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70

TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $40 to $70.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $60 to $100.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $52 to $110.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.

Benzinga Newsdesk